TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Median pH during combined dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nocturnal symptoms requiring albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School absence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Doctor contact
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: total apoB‐OxPL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoB‐100 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tear break up time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dryness symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Salivary output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Xerostomia relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximal INR increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in micturition frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in average micturition volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in episodes of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Spot urinary sodium levels >60 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary sodium/potassium ratio >2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to release from restraints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma concentrations of triacylglycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting concentrations of pancreatic polypeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma cholecystokinin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of depression
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of anxiety
Endpoint domain: Adverse events/effects
Primary endpoint: Median serum creatinine increment after 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of acute kidney injury
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical site infection (SSI) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative morphine consumption over 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine use between 24 and 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps strength on postoperative day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance ambulated on postoperative day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of combination pharmacotherapy vs monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of response rates at 72 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to place the ETT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LMA insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of attempts per device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in protecting from RF-EMF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prolonged QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in T wave morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory response (IL-6 levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulated C-peptide area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients achieving peak stimulated C-peptide > 0.2 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prediction of suboptimal cytoreduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: frequency of team behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UAV reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No obvious discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment administration acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: esophageal varices flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PCR uncorrected cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR corrected cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-h postprandial glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutrition knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to maintain a healthy body weight
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to eat fewer unhealthy foods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lower-leg growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost of radiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Obsessive-compulsive symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tic symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of genital ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Healing time of genital ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of completed modules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of completed assignments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of internal messages sent to therapist
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: End-tidal carbon dioxide monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Surgical comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of hematoma and reflex sympathetic dystrophy
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of contrast medium-induced kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: summed pain intensity difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective symptoms of motion sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: state-anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final decision quality scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: intersubjective agreement with physicians about decision quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delay in the transition to vaginal sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Instances of condomless sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Instances of vaginal or anal sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-perceived change in chest pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-post changes in body knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-post changes in protection methods knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical success rates of endodontically treated premolars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of bone invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIN2/3 diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute Kidney Injury (AKI) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total testosterone suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: VO(2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ET (exercise time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AI (arterial stiffness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health-related quality of life (EQ-5D and SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of protective antibody titer against A/Texas strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to reinitiation of anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant stability quotient values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRSr improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DRS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV(1) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in PSA slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3/4 toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in generalized tonic-clonic seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in tonic seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LV end-diastolic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence of C. difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: clearing of C. difficile culture and/or toxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean peak serum concentration (Cmax) of unchanged simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the serum simvastatin concentration-time curve (AUC(0-infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful pregnancy rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Intrahepatic lipid (IHL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in limb fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ham-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mediastinal chest tube drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for homologous transfusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: severity of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: questionnaire return rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of CHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antipsychotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication changes
Endpoint domain: Adverse events/effects
Primary endpoint: Drug side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in preventing rotavirus acute gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy in preventing severe rotavirus acute gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rise in serum neutralizing antibody to G1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of symptomatic ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: satisfactory bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 2-year infant survival without neurological impairment
Endpoint domain: Mortality/survival
Primary endpoint: drinking outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving successful result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse after treatment stopped
Endpoint domain: Adverse events/effects
Primary endpoint: Dependence on spectacles
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plasma ascorbic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma alpha-tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity of erythrocyte glutathione peroxidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psoriasis Area and Severity Index response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of new Gd(+) lesions evolving to T1 black holes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incremental cost-effectiveness ratio (QALY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Distance walked in 6 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed over 10 m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgeon's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hypertension frequency
Endpoint domain: Adverse events/effects
Primary endpoint: HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved metabolic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood flow or velocity in the vertebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety profile of vaccines
Endpoint domain: Adverse events/effects
Primary endpoint: Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: time to complete healing of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in End-CPB crystalloid fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative time to full mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ideational apraxia test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in ideomotor apraxia test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of errors in ideational apraxia test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of errors in ideomotor apraxia test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FIM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and acceptability of the HeLP Programme
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wound infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Energy availability from high-fiber diets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum IgM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of resuming work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Average platelet losses after filtration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequencies of residual WBCs in filtered platelet concentrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Filtration failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Motivation to notify partners about positive STI status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain with movement at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time until need for opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand strength in the Post-Anesthesia Care Unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-perceived ability to identify students in distress
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: confidence to help
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prothrombin time relationship with rivaroxaban plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Imaginative suggestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaginative ability (imagery vividness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less unprotected sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater proportion of protected sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less likely to test positive for an STD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Akathisia
Endpoint domain: Adverse events/effects